Humacyte (HUMA) Competitors

Zymeworks (NYSE:ZYME) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership.

Do analysts rate ZYME or HUMA?

Zymeworks presently has a consensus price target of $21.00, indicating a potential upside of 91.96%. Humacyte has a consensus price target of $13.71, indicating a potential upside of 790.54%. Given Humacyte's stronger consensus rating and higher probable upside, analysts plainly believe Humacyte is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88
Humacyte	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do insiders & institutionals have more ownership in ZYME or HUMA?

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 11.2% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has more risk & volatility, ZYME or HUMA?

Zymeworks has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Is ZYME or HUMA more profitable?

Humacyte has a net margin of 0.00% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-182.75%	-23.00%	-18.04%
Humacyte	N/A	-942.81%	-93.82%

Does the media prefer ZYME or HUMA?

In the previous week, Zymeworks had 2 more articles in the media than Humacyte. MarketBeat recorded 11 mentions for Zymeworks and 9 mentions for Humacyte. Humacyte's average media sentiment score of 1.66 beat Zymeworks' score of 1.12 indicating that Humacyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has higher earnings and valuation, ZYME or HUMA?

Humacyte has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$76.30M	9.98	-$118.67M	-$1.61	-6.80
Humacyte	$1.57M	152.15	-$110.78M	-$1.26	-1.22

Does the MarketBeat Community believe in ZYME or HUMA?

Zymeworks received 254 more outperform votes than Humacyte when rated by MarketBeat users. However, 70.18% of users gave Humacyte an outperform vote while only 67.74% of users gave Zymeworks an outperform vote.

Company	Underperform	Outperform
Zymeworks	Outperform Votes 294 67.74%	Underperform Votes 140 32.26%
Humacyte	Outperform Votes 40 70.18%	Underperform Votes 17 29.82%

Summary

Humacyte beats Zymeworks on 12 of the 18 factors compared between the two stocks.